BioMarin Pharma (Nasdaq: BMRN) announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for drisapersen for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE